Medivir AB

MVIR · Nasdaq Stockholm · Healthcare

1.69SEK +5.8%last day

Price as of 2 October 2026

The price over the past year, with dividends: +5.4%

Performance

1 month

−10.3%

1 year

+5.4%

3 years, per year

−34.1%

5 years, per year

−27.4%

Largest fall, 3 years

−95.7%

Below the peak now

−98.9%

Volatility, 1 year

149.5%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

3.4

Dividend yield

0.0%

Return on equity

−29.5%

Net margin

–

Market value

104 m USD

Quality, value and trend

Where Medivir stands against every Nordic stock today. 100 is best.

Quality63

Profitability and a sound balance sheet over time. Better than 63% of Nordic stocks.

Value8

The price measured against earnings, assets and cash flow. Better than 8% of Nordic stocks.

Trend37

The price development over the past year. Better than 37% of Nordic stocks.

Combined22

Quality, value and trend together. Better than 22% of Nordic stocks.

About Medivir

Medivir AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 6 employees.

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis